Pfizer Ltd reported a 10.4% rise in revenue to ₹2,519.65 crore for FY26. Despite a dip in net profit to ₹722.43 crore, the company recommended a ₹75 per share dividend, supported by strong EBITDA margins and new product launches. Investors can watch for impacts of price controls and competition.
Pfizer Ltd FY26 Results: Revenue Rises 10.4%, Dividend Declared
Pfizer Ltd's Net Sale of Products for FY 2026 was ₹2,377 crore. Profit for the Year was ₹722.43 crore.
Reader Takeaway: Revenue growth driven by new launches, but profit dips due to exceptional items.
What just happened
Pfizer Ltd announced its financial results for the fiscal year ended March 31, 2026. The company reported a revenue from operations of ₹2,519.65 crore, marking a 10.4% increase compared to the previous fiscal year. Net sales of products grew by 11.7% to ₹2,377.11 crore.
Profit for the year stood at ₹722.43 crore, a decrease of 5.9% from ₹767.60 crore in FY 2025. Profit before tax also saw a marginal decline of 4.0% to ₹975.67 crore. However, excluding exceptional items, profit before tax saw a 21.5% rise to ₹1,025 crore, indicating strong underlying operational performance.
Why this matters
This performance highlights the company's ability to grow its top line amidst market challenges, supported by successful new product introductions and strategic partnerships. The recommended dividend of ₹75 per equity share signifies confidence in its cash-generating capabilities and commitment to shareholder returns, despite a slight dip in net profit due to one-time charges.
The backstory
For FY 2026, Pfizer Ltd incurred exceptional items amounting to a net charge of ₹49.16 crore. This included ₹41.73 crore for personnel separation costs related to the Cipla partnership and costs arising from changes in wage definitions due to new labour codes.
What changes now
Pfizer has successfully launched new products such as Prevenar 20, Emblaveo, and Nurtec. Prevenar 20 quickly gained significant market share in its segment. The company also entered an exclusive distribution partnership with Cipla for key brands to expand its reach, particularly in Tier 2 and non-metro areas.
Risks to watch
The company faces potential risks from regulatory price controls under the Drug (Price Control) Order (DPCO), which could impact future growth. Additionally, increased generic competition in the oral anticoagulant market poses a challenge.
Peer comparison
While specific peer data for FY26 isn't provided in the filing, the pharmaceutical sector in India is highly competitive. Companies often leverage R&D, strategic alliances, and market access initiatives to drive growth and manage pricing pressures. Pfizer's strategy with Cipla aligns with broader industry trends of expanding reach through partnerships.
Context metrics (time-bound)
- Revenue from Operations (FY 2026): ₹2,519.65 crore (+10.4% YoY)
- Net Sale of Products (FY 2026): ₹2,377.11 crore (+11.7% YoY)
- Profit for the Year (FY 2026): ₹722.43 crore (-5.9% YoY)
- EBITDA Margin (FY 2026): 35.9%
- Recommended Dividend: ₹75 per equity share
What to track next
Investors should monitor the market performance and scalability of new launches like Prevenar 20. The impact of ongoing regulatory pricing policies and the success of the distribution partnership with Cipla will be key factors to watch for future growth and profitability.